New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2014
09:59 EDTWBMD, TQNT, TRXC, SWKS, SNDK, RFMD, PCL, NCLH, MHR, KRO, JAZZ, HAFC, GBDC, FMI, CVA, BNFT, ADHD, ACOR, ACRXOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AcelRx (ACRX) initiated with a Buy at Canaccord... Acorda Therapeutics (ACOR) initiated with a Hold at Canaccord... Alcobra (ADHD) initiated with a Buy at Canaccord... Benefitfocus (BNFT) initiated with a Market Perform at William Blair... Cameron (CAM) initiated with a Buy at Gabelli... Covanta (CVA) initiated with an Outperform at Macquarie... Foundation Medicine (FMI) initiated with a Market Perform at William Blair... Golub Capital (GBDC) initiated with an Outperform at Raymond James... Hanmi Financial (HAFC) initiated with an Outperform at Raymond James... Jazz Pharmaceuticals (JAZZ) initiated with a Buy at Canaccord... Kronos Worldwide (KRO) initiated with a Reduce at SunTrust... Magnum Hunter (MHR) initiated with a Hold at Maxim... Norwegian Cruise Line (NCLH) initiated with a Buy at Longbow... Plum Creek Timber (PCL) initiated with an Outperform at RBC Capital... RF Micro Devices (RFMD) initiated with a Market Perform at BMO Capital... SanDisk (SNDK) assumed with an Overweight at Piper Jaffray... Skyworks (SWKS) initiated with a Market Perform at BMO Capital... TransEnterix (TRXC) initiated with a Buy at Sterne Agee... TriQuint (TQNT) initiated with a Market Perform at BMO Capital... WebMD (WBMD) initiated with an Outperform at William Blair.
News For ACRX;ACOR;ADHD;BNFT;CVA;FMI;GBDC;HAFC;JAZZ;KRO;MHR;NCLH;PCL;RFMD;SNDK;SWKS;TRXC;TQNT;WBMD From The Last 14 Days
Check below for free stories on ACRX;ACOR;ADHD;BNFT;CVA;FMI;GBDC;HAFC;JAZZ;KRO;MHR;NCLH;PCL;RFMD;SNDK;SWKS;TRXC;TQNT;WBMD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 18, 2014
11:41 EDTJAZZCubist rises after report sparks takeover interest speculation
Subscribe for More Information
10:57 EDTACRXOptions with decreasing implied volatility
Subscribe for More Information
August 15, 2014
10:26 EDTSWKSSkyworks management to meet with Craig-Hallum
Subscribe for More Information
08:11 EDTJAZZJazz Pharmaceuticals management meeting strengthens postive view, says Cowen
Subscribe for More Information
07:23 EDTMHRMagnum Hunter management to meet with SunTrust
Subscribe for More Information
06:09 EDTNCLHNorwegian Cruise Line added to Focus List at Citigroup
Citigroup added Norwegian Cruise Line to its Focus List after its latest channel checks indicated the company's booking volume growth has accelerated to over 30% year-over-year. Citi believes investor sentiment is low and reiterates a Buy rating on Norwegian with a $40 price target.
August 14, 2014
17:46 EDTMHRRelational Investors gives quarterly update on stakes
NEW STAKES: Whole Foods Market (WFM). INCREASED STAKES: Clean Harbors (CLH), Magnum Hunter Resources (MHR), Manitowoc (MTW), Esterline Technologies (ESL), and Yum! Brands (YUM). DECREASED STAKES: Bunge (BG), and Hologic (HOLX). LIQUIDATED STAKES: W.R. Grace & Co (GRA), and First American Financial (FAF).
10:05 EDTADHDSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
August 13, 2014
06:02 EDTSNDKStocks with implied volatility below IV index mean; SNDK KMP
Subscribe for More Information
August 12, 2014
16:07 EDTFMIFoundation Medicine sees FY14 revenue $52M-$58M, consensus $58.01M
Sees Fy14 reported clinical tests in the range of 22,000-25,000.
16:06 EDTFMIFoundation Medicine reports Q2 EPS (49c), consensus (48c)
Reports Q2 revenue $14.5M, consensus $13.39M.
15:53 EDTJAZZCanaccord to hold a conference
34th Annual Growth Conference to be held in Boston on August 13-14.
08:01 EDTSWKSSkyworks price target raised to $62 from $55 at Canaccord
Canaccord raised its price target on Skyworks to $62 from $55 following investor meetings. The firm believes the company is well positioned to grow sales as well as expand its gross and operating margins and keeps its Buy rating on the shares.
August 11, 2014
16:05 EDTACRXAcelRx says disappointed on Zalviso CRL, to meet with FDA in September
"We were disappointed with the receipt of a Complete Response Letter for Zalviso and we look forward to meeting with the FDA to clarify the items included in the CRL and to discuss our planned response," stated Richard King, president and CEO of AcelRx. "We have spoken to the FDA and plan to meet with them by the end of September 2014. We anticipate we can refile the Zalviso NDA before the end of 2014, pending the outcome of the meeting with the FDA. We remain confident in the Zalviso development program and will work closely with the FDA to address the Agency's concerns as outlined in the CRL to ensure that healthcare professionals and patient communities will have access to Zalviso." The company reiterates and issues financial guidance for the year for total operating expenses to be in the range of $48M-$52M. Estimates cash, cash equivalents and investment balances at December 31 of at least $65M.
16:03 EDTACRXAcelRx reports Q2 EPS (30c), consensus (26c)
Subscribe for More Information
06:09 EDTSNDKStocks with implied volatility below IV index mean; GPRO SNDK
Stocks with implied volatility below IV index mean; GoPro (GPRO) 68, SanDisk (SNDK) 27 according to iVolatility.
August 8, 2014
08:56 EDTADHDAlcobra releases results from MRI study to evaluate effects of MDX
Alcobra released topline results from a pharmacological MRI study designed to evaluate the regions of the brain that are modulated by MDX. The study evaluated brain response to a single administration of Metadoxine in rats. The results showed that Metadoxine produced a significant, dose-dependent decrease in BOLD signal in highly selective regions of the brain including the prefrontal cortex and showed a statistically significant increase in BOLD response in brain regions including the central nucleus of the amygdala and the lateral hypothalamus. In addition, none of the mesolimbic dopamine system brain regions , known to be involved in the reinforcing effects of scheduled drugs, were significantly affected by Metadoxine at any dose level, which is consistent with previously presented data.
07:59 EDTBNFTBenefitfocus price target raised to $45 from $41 at Canaccord
Canaccord raised its price target on Benefitfocus (BNFT) to $45 from $41 following its better than expected Q2 results. The firm cited continued momentum, its United Health (UNH) win, and its potential to establish itself as one of the premier vendors in the benefits administration space. Canaccord keeps a Buy rating on Benefitfocus.
07:02 EDTMHRMagnum Hunter reports Q2 adjusted EPS (9c), consensus (17c)
Subscribe for More Information
06:02 EDTSNDKStocks with implied volatility below IV index mean; XLNK SNDK
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use